Elixinol Wellness (ASX:EXL) 5-Year EBITDA Growth Rate: 52.90% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Elixinol Wellness 5-Year EBITDA Growth Rate?

Elixinol Wellness ASX:EXL 5-Year EBITDA Growth Rate is 52.90% as of Dec. 2025. The stock has 7 warning signs investors should review.

Elixinol Wellness's EBITDA per Share for the six months ended in Dec. 2025 was A$-0.01.

During the past 3 years, the average EBITDA Per Share Growth Rate was 53.00% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 52.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 8 years, the highest 3-Year average EBITDA Per Share Growth Rate of Elixinol Wellness was 60.10% per year. The lowest was -241.60% per year. And the median was 53.00% per year.

Elixinol Wellness  (ASX:EXL) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Elixinol Wellness 5-Year EBITDA Growth Rate Related Terms

ASX:EXL vs ZTS, UTHR, VTRS: 5-Year EBITDA Growth Rate Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Elixinol Wellness's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Elixinol Wellness 5-Year EBITDA Growth Rate vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Elixinol Wellness's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Elixinol Wellness's 5-Year EBITDA Growth Rate falls into.


Elixinol Wellness 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

What does a 5-Year EBITDA Growth Rate of 52.90% mean?
Elixinol Wellness (ASX:EXL) has a 5-Year EBITDA Growth Rate of 52.90% as of Dec. 2025. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Elixinol Wellness and its competitors.
Is Elixinol Wellness' 5-Year EBITDA Growth Rate too high?
Elixinol Wellness' current 5-Year EBITDA Growth Rate is 52.90%.
How does Elixinol Wellness' 5-Year EBITDA Growth Rate compare to ZTS and UTHR?
Elixinol Wellness' 5-Year EBITDA Growth Rate of 52.90% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year EBITDA Growth Rate for a Drug Manufacturers company?
A good 5-Year EBITDA Growth Rate depends on the Drug Manufacturers industry context. However, 5-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year EBITDA Growth Rate mean?
A high 5-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 5-Year EBITDA Growth Rate is the 5-year average growth rate of EBITDA per share. View historical data for Elixinol Wellness and its competitors. Elixinol Wellness's current 5-Year EBITDA Growth Rate is 52.90%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elixinol Wellness stock overvalued right now?
Based on GuruFocus' analysis, Elixinol Wellness (ASX:EXL) is currently considered Possible Value Trap. The stock's GF Value™ is A$0.02, compared to a current price of A$0.01 — trading 65% below its estimated fair value. The current 5-Year EBITDA Growth Rate is 52.90%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year EBITDA Growth Rate calculated?
5-Year EBITDA Growth Rate is calculated from a company's financial statements. For Elixinol Wellness (ASX:EXL), the current 5-Year EBITDA Growth Rate is 52.90% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elixinol Wellness Business Description

Other Exchanges ELLXF:USAE8M:Germany
Address 51 - 53 Riversdale Road, Newtown, VIC, AUS, 3220
Elixinol Wellness Ltd is engaged in the hemp industry, innovating, marketing, and selling hemp-derived nutraceutical, cosmetic, and food products. It operates in the three operating segments of the Americas, Australia, Rest of the World regions of which key revenue is derived from the Australia segment. The Australia segment includes the results from operations of Elixinol Wellness (Byron Bay) Pty Ltd and The Sustainable Nutrition Group Pty Ltd and its subsidiaries. It derives maximum revenue from Australia.